Related content

Targeting the dopamine D₁ receptor in schizophrenia: insights for cognitive dysfunction

By Goldman-Rakic Patricia   Castner Stacy   Svensson Torgny   Siever Larry   Williams Graham  

Psychopharmacology, Vol. 174, Iss. 1, 2004-06 ,pp. : 3-16

Springer Publishing Company

Access to resources Recommend Favorite

Cognitive Dysfunction in Depression: Lessons Learned from Animal Models

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 10, 2014-12 ,pp. : 1860-1870

Bentham Science Publishers

Access to resources Recommend Favorite

Glutamatergic Animal Models of Schizophrenia

By  

Current Pharmaceutical Design, Vol. 18, Iss. 12, 2012-04 ,pp. : 1593-1604

Bentham Science Publishers

Access to resources Recommend Favorite

Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction

By Lewis David   Volk David   Hashimoto Takanori  

Psychopharmacology, Vol. 174, Iss. 1, 2004-06 ,pp. : 143-150

Springer Publishing Company

Access to resources Recommend Favorite

New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function

By  

Current Neuropharmacology, Vol. 13, Iss. 6, 2015-12 ,pp. : 793-801

Bentham Science Publishers

Access to resources Recommend Favorite